SMMT
Summit Achieves Significant Milestones in Q2 2026 as Ivonescimab Continues to Impress
Summit, a leading biopharmaceutical company, recently concluded its quarterly conference call for Q2 2026, highlighting notable achievements and updates on its flagship asset, ivonescimab. The presentation, led by Chairman of the Board Bob Duggan, Co-Chief Executive Officers Dr. Maky Zanganeh and Manmeet Soni, along with Chief Research and Development Strategy